German medtech startup Altavo GmbH has closed a 3 million euros Series A2 financing round to accelerate the development of its Artificial Voice technology, aimed at restoring natural-sounding speech for people who have lost their voice.
The round, completed on January 12, 2026, is backed by a European investor consortium led by Novalis Biotech and Beteiligungsmanagement Thüringen, highlighting a strong Belgian–German link in the company’s growth story.
Additional investors include TGFS Technologiegründerfonds Sachsen, High-Tech Gründerfonds (HTGF), TUDAG TU Dresden AG, Ostwerk GmbH and several private investors.
Altavo’s technology targets voiceless patients, such as those who have undergone a laryngectomy or are dependent on mechanical ventilation. Its “silent speech” solution combines non-invasive radar sensing with advanced AI algorithms to reconstruct a patient’s own voice. The system is being developed in close collaboration with researchers at Dresden University of Technology.
The fresh funding will be used to support company growth, clinical development and the transition toward a commercial product. According to CEO and co-founder Rudolf von Bünau, the Series A2 round positions Altavo well for the next phase in bringing an Artificial Voice to market.
From a Belgian perspective, Novalis Biotech’s involvement underlines the cross-border interest in deeptech and medtech innovation emerging from Germany. Investment manager Jaroslav Belotserkovsky cited Altavo’s clinical progress and experienced leadership as key reasons for joining the round.
Founded in 2021, Altavo employs 16 people across its Dresden and Jena locations and focuses on AI-driven prosthetic solutions for aphonic and severely voice-impaired patients. Its academic partnerships and EU-supported research projects position the company at the intersection of medical devices, artificial intelligence and speech technology — an area increasingly attracting attention from European investors.
